M. Bruncko

发表

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

S. Korsmeyer, A. Letai, P. Hajduk, 2005, Nature.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Wang Shen, Mary K Joseph, Saul H Rosenberg, 2006, Cancer research.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

A. Petros, S. Fesik, S. Ng, 2006, Journal of medicinal chemistry.

Comprehensive Middle-Down Mass Spectrometry Characterization of an Antibody-Drug Conjugate by Combined Ion Activation Methods.

J. Brodbelt, M. Bruncko, Jon D. Williams, 2020, Analytical chemistry.

Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs.

Brittney J. Mills, M. Bruncko, F. Jameel, 2020, Journal of pharmaceutical sciences.

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

C. Tse, D. Anderson, Daniel J. Anderson, 2015, Cell Death and Disease.

Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

Saul H Rosenberg, Xiaohong Song, Milan Bruncko, 2008, Journal of medicinal chemistry.

Synthesis and reactions of 5-acetyl-2-amino-3-cyano-4-(5-X-2-furyl)-6-methyl-4 H -pyrans

M. Bruncko, J. Kováč, S. Marchalin, 1990 .

Synthese von 4H-Pyrano[2,3-d]pyrimidinen

M. Bruncko, Štefan Marchalín, Dušan Ilavský, 1989 .

Allylic Amination and 1,2‐Diamination with a Modified Diimidoselenium Reagent

M. Bruncko, T. A. Khuong, K. B. Sharpless, 1996 .

Dihydropyridine‐Based Calcium Channel Blockers for the Treatment of Angina Pectoris and Hypertension

M. Bruncko, 2013 .

Cyclic Tautomers of Tryptophan: Enantio- and Diastereoselective Synthesis of .beta.-Substituted and .alpha.,.beta.-Disubstituted Derivatives of Tryptophan

M. Bruncko, D. Crich, 1994 .

N‐Bromoacetamide—A New Nitrogen Source for the Catalytic Asymmetric Aminohydroxylation of Olefins

M. Bruncko, K. B. Sharpless, G. Schlingloff, 1997 .

Asymmetric synthesis of a taxol C-ring by aldol condensation and radical cyclization

M. Bruncko, D. Crich, Xian-yun Jiao, 1997 .

Conformational analysis of substituted hexahydropyrrolo [2,3-b]indoles and related systems. An unusual example of hindered rotation about sulfonamide SN bonds. An X-ray crystallographic and NMR study

M. Bruncko, S. Natarajan, D. Tocher, 1995 .

Conformationally restricted amino acids: Diastereoselective substitution at the β-position of L-tryptophan

M. Bruncko, D. Crich, 1992 .

Chemistry of Cyclic Tautomers of Tryptophan: Formation of a Quaternary Center at C3a and Total Synthesis of the Marine Alkaloid (+)-ent-Debromoflustramine B

M. Bruncko, D. Crich, R. Samy, 1994 .

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Mary K Joseph, Saul H Rosenberg, Xiaohong Song, 2007, Journal of medicinal chemistry.

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Xin Lu, J. Leverson, W. N. Pappano, 2015, Molecular Cancer Therapeutics.

Functionalization at C-3a of Tryptophan Derived Hexahydropyrrolo[2,3-b]indoles

M. Bruncko, D. Crich, R. Samy, 1993 .

1‐Phenyl‐2‐tetrazoline‐5‐thione

M. Bruncko, R. Taylor, Zhendong Jin, 2015 .

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor

Xiaohong Song, Z. Tao, P. Kovar, 2020, ACS medicinal chemistry letters.

N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.

Jun Chen, Saul H Rosenberg, Xiaohong Song, 2010, Bioorganic & medicinal chemistry letters.

Novel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening

A. Korkegian, D. Kempf, M. Files, 2022, Scientific Reports.

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Xin Lu, J. Leverson, S. Elmore, 2015, Molecular Cancer Therapeutics.

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.

Milan Bruncko, V. Giranda, D. Sauer, 2005, Bioorganic & medicinal chemistry letters.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

A. Petros, S. Fesik, S. Ng, 2006, Journal of medicinal chemistry.